Gilead to develop hepatitis B therapies using Precision’s ARCUS genome editing platform.

Gilead Sciences will use Precision BioScience’s ARCUS genome editing platform to develop therapies targeting the in vivo elimination of hepatitis B virus (HBV). The companies cited preliminary studies at Gilead using ARCUS nucleases to target HBV covalently closed circular DNA (cccDNA) in vitro, which they said have shown “significant” activity against cccDNA and integrated HBV DNA in human hepatocytes.